54877-27-9

Usage

Uses

1. Used in Chemical Synthesis:
1-(3-Bromopropyl)-2-chlorobenzene is used as a chemical intermediate for the synthesis of various organic compounds. Its reactive bromine and chlorine atoms make it a valuable building block in the creation of complex molecules for different applications.
2. Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-(3-Bromopropyl)-2-chlorobenzene is used as a key component in the development of new drugs. Its unique structure allows for the formation of various drug candidates with potential therapeutic properties.
3. Used in Pest Control Industry:
1-(3-Bromopropyl)-2-chlorobenzene is used in the preparation of tetrazolinone compounds, which are effective as pest control agents. These compounds are utilized in the development of pesticides to protect crops and control pests in the agricultural sector.
4. Used in Material Science:
In the field of material science, 1-(3-Bromopropyl)-2-chlorobenzene can be used to develop new materials with specific properties, such as improved stability, reactivity, or selectivity. Its unique structure can contribute to the creation of advanced materials for various applications, including electronics, coatings, and adhesives.
5. Used in Research and Development:
1-(3-Bromopropyl)-2-chlorobenzene is also used in research and development laboratories for the exploration of new chemical reactions and the synthesis of novel compounds. Its versatility as a starting material makes it an essential tool for chemists working on the development of new molecules and materials.

InChI:InChI=1/C9H10BrCl/c10-7-3-5-8-4-1-2-6-9(8)11/h1-2,4,6H,3,5,7H2

Upstream product

• 6282-87-7 3-(2-chlorophenyl)-propanol 
• 74124-86-0 3-chlorophenylpropionic acid methyl ester 
• 98288-14-3 methyl (2E)-3-(2-chlorophenyl)prop-2-enoate 
• 89-98-5 2-chloro-benzaldehyde 
• 704-96-1 trans-2-chlorocinnamic acid 
• 615-41-8 2-iodochlorobenzene 

Downstream Products

• 68449-31-0 4-(2-chlorophenyl)butanoic acid 
• 14491-45-3 1-Brom-5-(2-chlor-phenyl)-pentan 
• 18742-18-2 [5-(2-chloro-phenyl)-pentyl]-diphenyl-silane 
• 18768-24-6 Dibenzyl-<3-(o-chlor-phenyl)-propyl>-phenyl-silan 
• 18751-15-0 1-phenyl-1-o-tolyl-1,2,3,4-tetrahydro-benzo[b]siline 
• 18766-15-9 1,1-diphenyl-1,2,3,4,5,6-hexahydro-benzo[b]silocine 
• 17908-94-0 1-phenyl-1,2,3,4-tetrahydro-benzo[b]siline 
• 17922-13-3 1-methyl-1-phenyl-1,2,3,4-tetrahydro-benzo[b]siline 
• 1092-88-2 1,1-diphenyl-1,2,3,4-tetrahydro-benzo[b]siline 
• 736911-12-9 4-(2-Chlorophenyl)-1-(1H-imidazol-4-yl)-butan-1-ol 
• 17146-05-3 Chlor-<3-(2-chlor-phenyl)-propyl>-dimethyl-silan 
• 18751-19-4 [3-(2-chloro-phenyl)-propyl]-phenyl-o-tolyl-silane 
• 18742-19-3 <3-(o-Chlor-phenyl)-propyl>-dibenzylsilan 
• 1730-88-7 [3-(2-chloro-phenyl)-propyl]-diphenyl-silane 

Relevant academic research and scientific papers

Expedient Access to 2-Benzazepines by Palladium-Catalyzed C?H Activation: Identification of a Unique Hsp90 Inhibitor Scaffold

Bioactive 2-benzazepines were accessed in an atom- and step-economical manner through a versatile palladium-catalyzed C?H activation strategy. The C?H arylation required low catalyst loading and a mild base, which was reflected by a broad scope and high functional-group tolerance. The benzotriazolodiazepinones were identified as new heat shock protein 90 (Hsp90) inhibiting lead compounds, with considerable potential for anti-cancer applications.

Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects

The recent discovery that small molecule ligands for the peptidyl-prolyl isomerase (PPIase) FKBP12 possess powerful neuroprotective and neuroregenerative properties in vitro and in vivo suggests therapeutic utility for such compounds in neurodegenerative disease. The neurotrophic effects of these compounds are independent of the immunosuppressive pathways by which drugs such as FK506 and rapamycin operate. Previous work by ourselves and other groups exploring the structure-activity relationships (SAR) of small molecules that mimic only the FKBP binding domain portion of FK506 has focused on esters of proline and pipecolic acid. We have explored amide and thioester analogues of these earlier structures and found that they too are extremely potent in promoting recovery of lesioned dopaminergic pathways in a mouse model of Parkinson's disease. Several compounds were shown to be highly effective upon oral administration after lesioning of the dopaminergic pathway, providing further evidence of the potential clinical utility of a variety of structural classes of FKBP12 ligands.